Terms: = Lung cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Clinical Outcome
17 results:
1. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse outcomes in Patients With EGFR-Mutant lung cancer.
Stockhammer P; Grant M; Wurtz A; Foggetti G; Expósito F; Gu J; Zhao H; Choi J; Chung S; Li F; Walther Z; Dietz J; Duffield E; Gettinger S; Politi K; Goldberg SB
J Thorac Oncol; 2024 Feb; 19(2):240-251. PubMed ID: 37806385
[TBL] [Abstract] [Full Text] [Related]
2. Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients.
Bruschini S; Pallocca M; Sperandio E; D'Ambrosio L; Ascenzi F; De Vitis C; Salvati V; Esposito A; Di Martino S; De Nicola F; Paolini F; Fattore L; Alessandrini G; Facciolo F; Foddai ML; Bassi M; Venuta F; D'Ascanio M; Ricci A; D' Andrilli A; Napoli C; Aurisicchio L; Fanciulli M; Rendina EA; Ciliberto G; Mancini R
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35584864
[TBL] [Abstract] [Full Text] [Related]
3. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure.
Lin Z; Huang L; Li S; Gu J; Cui X; Zhou Y
Sci Rep; 2020 Dec; 10(1):21530. PubMed ID: 33299035
[TBL] [Abstract] [Full Text] [Related]
4. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the iris study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract] [Full Text] [Related]
5. Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.
Pillappa R; Maleszewski JJ; Sukov WR; Bedroske PP; Greipp PT; Boland JM; Yi ES; Peikert T; Aubry MC; Roden AC
Am J Surg Pathol; 2018 Feb; 42(2):256-263. PubMed ID: 29076876
[TBL] [Abstract] [Full Text] [Related]
6. Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.
Zhou H; Dai Y; Zhu L; Wang C; Fei X; Pan Q; Chen J; Shi X; Yang Y; Tao X; Shi P
J Int Med Res; 2016 Feb; 44(1):89-98. PubMed ID: 26740498
[TBL] [Abstract] [Full Text] [Related]
7. Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell lung cancer.
Grossi F; Dal Bello MG; Salvi S; Puzone R; Pfeffer U; Fontana V; Alama A; Rijavec E; Barletta G; Genova C; Sini C; Ratto GB; Taviani M; Truini M; Merlo DF
Dis Markers; 2015; 2015():302649. PubMed ID: 26663950
[TBL] [Abstract] [Full Text] [Related]
8. Correlation between brca1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Wang LR; He LJ; Wang Y; Li YY; Lou Y; Zhang GB; Li Y; Chen J
Cancer Chemother Pharmacol; 2015 Jul; 76(1):163-70. PubMed ID: 26003539
[TBL] [Abstract] [Full Text] [Related]
9. Predictive value of APE1, brca1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract] [Full Text] [Related]
10. Predictive role of RRM1 and brca1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer.
Liang JG; Jin ZY; Gao XD; Te MR; Ge LH; Wang CL
Genet Mol Res; 2014 Jul; 13(3):5292-8. PubMed ID: 25078585
[TBL] [Abstract] [Full Text] [Related]
11. Expression of ERCC1 and brca1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy.
Wang TB; Zhang NL; Wang SH; Li HY; Chen SW; Zheng YG
Genet Mol Res; 2014 May; 13(2):3704-10. PubMed ID: 24854656
[TBL] [Abstract] [Full Text] [Related]
12. ERCC1 and brca1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Qin X; Yao W; Li W; Feng X; Huo X; Yang S; Zhao H; Gu X
Tumour Biol; 2014 May; 35(5):4697-704. PubMed ID: 24443257
[TBL] [Abstract] [Full Text] [Related]
13. Breast cancer susceptibility gene 1 (brca1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis.
Yang Y; Xie Y; Xian L
J Exp Clin Cancer Res; 2013 Mar; 32(1):15. PubMed ID: 23497550
[TBL] [Abstract] [Full Text] [Related]
14. Gene expression from bronchoscopy obtained tumour samples as a predictor of outcome in advanced inoperable lung cancer.
Suwinski R; Klusek A; Tyszkiewicz T; Kowalska M; Szczesniak-Klusek B; Gawkowska-Suwinska M; Tukiendorf A; Kozielski J; Jarzab M
PLoS One; 2012; 7(7):e41379. PubMed ID: 22848476
[TBL] [Abstract] [Full Text] [Related]
15. Tubulin, brca1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Joerger M; deJong D; Burylo A; Burgers JA; Baas P; Huitema AD; Beijnen JH; Schellens JH
Lung Cancer; 2011 Nov; 74(2):310-7. PubMed ID: 21529986
[TBL] [Abstract] [Full Text] [Related]
16. ERCC1, RRM1 and brca1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
Su C; Zhou S; Zhang L; Ren S; Xu J; Zhang J; Lv M; Zhang J; Zhou C
Med Oncol; 2011 Dec; 28(4):1411-7. PubMed ID: 20467918
[TBL] [Abstract] [Full Text] [Related]
17. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.
Kim YH; Ishii G; Goto K; Ota S; Kubota K; Murata Y; Mishima M; Saijo N; Nishiwaki Y; Ochiai A
Lung Cancer; 2009 Jul; 65(1):105-11. PubMed ID: 19036469
[TBL] [Abstract] [Full Text] [Related]